CN117043191A - 糖蛋白vi的纳米抗体 - Google Patents

糖蛋白vi的纳米抗体 Download PDF

Info

Publication number
CN117043191A
CN117043191A CN202180094483.4A CN202180094483A CN117043191A CN 117043191 A CN117043191 A CN 117043191A CN 202180094483 A CN202180094483 A CN 202180094483A CN 117043191 A CN117043191 A CN 117043191A
Authority
CN
China
Prior art keywords
ser
gly
ala
tyr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180094483.4A
Other languages
English (en)
Chinese (zh)
Inventor
亚历山大·斯莱特
纳塔莉·萨拉·波尔特
马克·罗伯特·托马斯
史蒂夫·保罗·沃森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Birmingham
Original Assignee
University of Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Birmingham filed Critical University of Birmingham
Publication of CN117043191A publication Critical patent/CN117043191A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180094483.4A 2020-12-24 2021-12-21 糖蛋白vi的纳米抗体 Pending CN117043191A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2020602.5A GB202020602D0 (en) 2020-12-24 2020-12-24 Nanobody
GB2020602.5 2020-12-24
PCT/EP2021/087129 WO2022136457A1 (en) 2020-12-24 2021-12-21 Nanobody to glycoprotein vi

Publications (1)

Publication Number Publication Date
CN117043191A true CN117043191A (zh) 2023-11-10

Family

ID=74532190

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180094483.4A Pending CN117043191A (zh) 2020-12-24 2021-12-21 糖蛋白vi的纳米抗体

Country Status (7)

Country Link
US (1) US20240067721A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267624A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024500946A (cg-RX-API-DMAC7.html)
CN (1) CN117043191A (cg-RX-API-DMAC7.html)
CA (1) CA3203202A1 (cg-RX-API-DMAC7.html)
GB (1) GB202020602D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022136457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019685A1 (en) * 2024-07-17 2026-01-22 Harpoon Therapeutics, Inc. Her2 targeting trispecific protein for treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130543D0 (en) * 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
US20090130021A1 (en) * 2002-06-07 2009-05-21 Gotz Munch Methods, products and uses involving platelets and/or the vasculature
WO2007091719A1 (ja) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 抗gpvi抗体の併用療法及び新規医薬用途
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
JP5843783B2 (ja) * 2009-12-18 2016-01-13 サノフイ GPVIに対する新規アンタゴニスト抗体および該抗体のFabフラグメントならびにこれらの使用

Also Published As

Publication number Publication date
EP4267624A1 (en) 2023-11-01
WO2022136457A1 (en) 2022-06-30
US20240067721A1 (en) 2024-02-29
CA3203202A1 (en) 2022-06-30
JP2024500946A (ja) 2024-01-10
GB202020602D0 (en) 2021-02-10

Similar Documents

Publication Publication Date Title
JP7047017B2 (ja) 黄色ブドウ球菌(Staphylococcus aureus)α毒素に特異的に結合する抗体及び使用方法
KR102700015B1 (ko) 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
KR102914586B1 (ko) 메소텔린 및 cd3에 결합하는 이중특이적 항체 작제물
KR102735615B1 (ko) Egfrviii 및 cd3에 결합하는 이중특이적 항체 작제물
JP6693872B2 (ja) 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
US9045538B2 (en) Anti-glycoprotein VI scFv fragment for treatment of thrombosis
JP7785450B2 (ja) Muc17及びcd3に向けられる二重特異性抗体コンストラクト
KR20260028110A (ko) 이중특이성 t 세포 맞물림 항체 작제물
CN106163556A (zh) 基质金属蛋白酶底物和其它可切割部分及其使用方法
US12617863B2 (en) Humanized anti-glycoprotein Ib alpha (GPIbalpha) antibodies
US11542329B2 (en) Antibodies targeting Glycoprotein VI
US20240067721A1 (en) Nanobody to glycoprotein vi
US20240247076A1 (en) Coagulation factor xi (fxi) binding protein
CN107614524A (zh) 治疗
HK40108701A (en) Antibody constructs for msln and cd3
HK40038870B (en) Humanized anti-glycoprotein ib alpha antibodies and use thereof
HK40038870A (en) Humanized anti-glycoprotein ib alpha antibodies and use thereof
HK1191977A (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
HK1191977B (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination